Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Debt to Equity (2016 - 2021)

International Stem Cell (ISCO) has disclosed Debt to Equity for 10 consecutive years, with -$0.11 as the latest value for Q2 2021.

  • On a quarterly basis, Debt to Equity changed N/A to -$0.11 in Q2 2021 year-over-year; TTM through Jun 2021 was -$0.11, a N/A change, with the full-year FY2020 number at -$0.6, up 26.43% from a year prior.
  • Debt to Equity was -$0.11 for Q2 2021 at International Stem Cell, up from -$0.24 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $2.05 in Q1 2017 to a low of -$14.78 in Q3 2017.
  • A 5-year average of -$1.09 and a median of -$0.17 in 2020 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 164401.14% in 2017; the steepest drop was 24267.7% in 2017.
  • International Stem Cell's Debt to Equity stood at -$14.78 in 2017, then surged by 104.65% to $0.69 in 2018, then tumbled by 219.31% to -$0.82 in 2019, then increased by 26.43% to -$0.6 in 2020, then skyrocketed by 81.71% to -$0.11 in 2021.
  • Per Business Quant, the three most recent readings for ISCO's Debt to Equity are -$0.11 (Q2 2021), -$0.24 (Q1 2021), and -$0.6 (Q4 2020).